Dongxing Medical: Intends to acquire 90% equity of Wuhan Yijia Bao, expected to constitute a significant asset restructuring.

EastStar Medical announced that it plans to purchase 90% of the equity of Wuhan Yijiaobao Biological Materials Co., Ltd. by paying cash, which is expected to constitute a significant asset restructuring. The transaction parties are all shareholders of Wuhan Yijiaobao, including Bao Shijun and Hubei Tianhui Technology Development Co., Ltd. After the transaction is completed, Wuhan Yijiaobao will become a subsidiary of the company. The transaction is still in the preliminary planning stage, and the specific acquisition equity ratio, transaction parties, and transaction price still need to be further negotiated and determined.